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Sapropterin dihydrochloride (BH4) reduces phenylalanine (Phe) levels and improves white matter integrity in a
subset of individuals with phenylketonuria (PKU) known as “responders.” Although prior research has identiﬁed
biochemical and genotypic differences betweenBH4 responders and non-responders, cognitive and neural differ-
ences remain largely unexplored. To this end,we compared intelligence andwhitematter integrity prior to treat-
mentwith BH4 in 13 subsequent BH4 responderswith PKU, 16 subsequent BH4 non-responderswith PKU, and 12
healthy controls. Results indicated poorer intelligence andwhitematter integrity in non-responders compared to
responders prior to treatment. In addition, poorer white matter integrity was associated with greater variability
in Phe across the lifetime in non-responders but not in responders. These results underscore the importance of
considering PKU as a multi-faceted, multi-dimensional disorder and point to the need for additional research
to delineate characteristics that predict response to treatment with BH4.
© 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Phenylketonuria (PKU) is a recessive hereditary disorder character-
ized by deﬁcient or absent phenylalanine hydroxylase (PAH).
Consequently, catalysis of phenylalanine (Phe) is disrupted, and con-
centrations of blood Phe are elevated [36]. If untreated, PKU may lead
to profound neurologic problems and intellectual disability [31,32].
In recent decades, themost severe of these neural and cognitive con-
sequences have been mitigated by newborn screening programs that
identify infants with PKU and implement dietary treatment to limit
Phe intake. Nevertheless, individuals with early- and continuously-
treated PKU exhibit brain abnormalities [2,3,8,11], score slightly lower
than expected on tests of intelligence [35], and are at increased risk
for executive (for review, see [10]), psychosocial, and psychiatric difﬁ-
culties [9,20,43].
Dietary restriction of Phe-containing foods remains the most com-
monly prescribed treatment for PKU, but emerging treatments hold
promise for the future [40,45]. One promising pharmaceutical treat-
ment is a synthetic form of tetrahydrobiopterin (BH4), sapropterin
dihydrochloride. BH4 is a cofactor for PAH, facilitating the conversion
of Phe into tyrosine and thereby reducing blood Phe in a subset of indi-
viduals with PKU who have residual PAH activity [30].
Although there is some debate regarding the degree to which blood
Phe must be reduced to consider an individual a responder to BH4 [38,
46], responsiveness is often deﬁned as a reduction in Phe ≥ 30% com-
pared to a pretreatment baseline [6]. In the present study, BH4 re-
sponders exhibited average reductions in Phe ≥ 30% over the course of
4 weeks of treatment. Previous studies using a similar reduction criteri-
on found that 38–54% of individuals with PKU responded to BH4 within
8 h of administration [18,19], 46–52% responded within 24 h of admin-
istration [18,19], and 50% respondedwithin 48 h of administration [19].
Factors distinguishing BH4 responders from non-responders are not
well understood. Although evidence suggests that individuals with mild
PKU respond better than those with classic PKU [26], a subset of individ-
ualswith classic PKUnonetheless respond to the drug [21,29]. In addition,
biochemical [22,25] and genetic [22,26,34] variables may differ between
responders and non-responders. For example, in the biochemical domain,
Humphrey et al. [25] found that non-responders typically have greater
variability in bloodPhe and ahigher Phe to tyrosine ratio than responders.
In the genetic domain, Karačić et al. [26] linkedBH4 responsiveness tomu-
tations on the 12q22-24 chromosome of the gene encoding PAH.
In contrast with the proliferation of research on biochemical and ge-
netic differences between BH4 responders and non-responders, cogni-
tive and neural differences remain largely unexplored. The present
study aimed to address this gap in knowledge. To do so, we examined
data related to indices of Phe control, microstructural white matter in-
tegrity, and intelligence that were collected prior to BH4 administration
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in individuals whowere subsequently identiﬁed as BH4 responders and
non-responders. To provide a normative context for results, compari-
sons were also made with a healthy non-PKU control group.
2. Material and methods
2.1. Participants
Individuals with classic PKU (n=29; 18males, 11 females) were re-
cruited through metabolic clinics at St. Louis Children's Hospital (n =
11), University of Missouri (n = 7), University of Florida (n = 4), St.
Louis University (n = 3), Washington University (n = 2), New York
Medical College (n = 1), and University of Nebraska (n = 1), with all
cognitive assessment and neuroimaging procedures conducted at either
Washington University (n=19) or University of Missouri (n=10). All
individuals were diagnosed in early infancy and thereafter placed on
continuous dietary treatment to limit Phe intake. No individual had a
history of major medical, psychiatric, or learning disorder unrelated to
PKU.
Baseline cognitive, neuroimaging, and blood Phe data were obtained
from participants prior to treatment with BH4 (20 mg/kg/day). During
the 4 weeks of screening for response to BH4 that followed, blood Phe
was monitored weekly, and participants were instructed to maintain
their usual diets. Phe levels recorded in the year preceding treatment
were averaged to calculate baseline Phe, and Phe levels from the 4-
week screening period were averaged to calculate percent reduction
in blood Phe relative to baseline Phe. On this basis, individuals were
classiﬁed as responders or non-responders to BH4 (Phe data are report-
ed in Table 3; secondary analyseswere also run using lifetimemean Phe
as the baseline metric against which screening Phe was compared, and
results were consistent). Responders (n= 13; 8 males, 5 females) ex-
hibited a reduction in Phe ≥ 30%, whereas non-responders (n = 16;
10 males, 6 females) failed to exhibit such change.
Age ranged from 9–35 years (M = 18.8, SD = 9.4) for responders
and 8–33 years (M = 16.6, SD = 8.1) for non-responders. Pertaining
to race/ethnicity, 8% of responders and 0% of non-responders identiﬁed
as members of a minority group. There were no signiﬁcant differences
between responders and non-responders in age, gender, or race/ethnic-
ity (p N 0.05 in all instances).
Baseline cognitive and neuroimaging data from individuals with
PKU were also compared with those of healthy controls (n = 12; 8
males, 4 females) recruited from the St. Louis community. Within the
control group, age ranged from 7–33 years (M = 17.8, SD = 8.0), and
8% identiﬁed asmembers of aminority group. No control reported a his-
tory of major medical, psychiatric, or learning disorder, and there were
no signiﬁcant differences between individuals with PKU and controls in
age, gender, or race/ethnicity (p N 0.05 in all instances).
2.2. Procedures
Data included in this report are components of a longitudinal study
exploring the effects of BH4 on biochemical, neural, and cognitive out-
comes in individuals with early- and continuously-treated PKU. Ap-
proval for this study was obtained from institutional review boards at
Washington University and University of Missouri, the sites at which
all cognitive and neuroimaging data were collected. Participants and/
or their guardians provided written informed consent prior to enrolling
in the study, and the cognitive and neuroimaging components of the
study were typically completed in a single session lasting 4 h. Previous
manuscripts have reported data from the longitudinal dataset to ex-
plore differences in cognition and white matter integrity between PKU
and control groups1; however, pretreatment cognitive and neural
differences between responders and non-responders have not been ex-
amined previously.
2.3. Phenylalanine
We evaluated 6 indices of Phe control. Of these indices, 3 were relat-
ed to implementation of treatment with BH4 (baseline Phe, screening
Phe, percent reduction in Phe) and 3 were related to Phe control over
the lifetime prior to treatment with BH4 (mean Phe, SD Phe as an indi-
cator of variability, index of dietary control [IDC]). Baseline and screen-
ing Phe were used to calculate percent reduction in Phe, thereby
determining group status (i.e., responder, non-responder). Lifetime
mean Phe and SD Phewere examined because they have been negative-
ly associated with cognitive performance and white matter integrity
[23,24,41] and are used with greatest ease in metabolic clinics. The
IDC was examined to control for the fact that fewer Phe levels are typi-
cally obtained as individuals with PKU age; this index was computed as
themean of each individual's annualmedian Phe level, and thus provid-
ed a weighted average of lifetime Phe.
2.4. Intelligence
IQ was estimated using a composite based on standard scores (stan-
dard score normativemean=100, SD=15) from theMatrix Reasoning
and Vocabulary subtests of the Wechsler Abbreviated Scale of Intelli-
gence (WASI; [42]). The two subtest scores were also examined sepa-
rately because they provided estimates of performance and verbal IQ,
respectively. Administration and scoring followed test manual
instructions.
2.5. White matter integrity
Neuroimaging procedures are described in detail by Antenor-Dorsey
et al. [3]. Brieﬂy, scans were run on a Siemens TIM Trio 3.0 T imaging
system (Erlangen, Germany). Diffusion tensor imaging (DTI) data
reﬂecting microstructural white matter integrity were collected using
an echo planar imaging (EPI) sequence along 25 non-collinear diffusion
gradients [TR = 12,437 (Washington University; WU) and 9900 (Uni-
versity of Missouri; UM), TE = 102 (WU and UM), ﬂip angle = 90°
(WU and UM), FOV= 864 × 864 (WU) and 768 × 768 (UM), voxel res-
olution = 2.0 × 2.0 × 2.0 (WU and UM)]. Diffusion weighted images
were registered to weighted structural images and then to an in-
house atlas at Washington University. Parametric maps were subse-
quently generated for mean diffusivity (MD), the DTI component of in-
terest in this study.
MDwas compared across study groups using region of interest (ROI)
and tract based spatial statistics (TBSS) analyses (FSL software, Oxford,
UK; [39]). We did not control for age because groups were statistically
equivalent on this metric, and previous analyses of DTI and cognition
did not indicate signiﬁcant interactions between age and group [3]. As
in our previous studies [3,23,44], we focused on the following 10
white matter ROIs to provide a broad sampling across a range of brain
regions: hippocampus, putamen, prefrontal cortex, optic radiation, pos-
terior parietal-occipital, centrum semiovale, thalamus, and corpus
callosum (genu, body, splenium). MD data from two non-responders
were unavailable due to MRI contraindications and movement artifact,
but this did not result in between-group demographic differences.
2.6. Statistical analyses
As a starting point, tominimize the number of group-wise (responder,
non-responder, control) comparisons and thereby reduce Type I error
rate, omnibus ANOVAs were conducted to examine the effect of group
(responder, non-responder, control) on each intelligence and MD vari-
able.When signiﬁcant ANOVA resultswere obtained, one-tailed indepen-
dent samples t-tests were conducted to examine the effect of group on
1 Sample size may differ slightly across studies due to variations in exclusion criteria.
The present study excluded participants if response to BH4 was unknown, IQ data were
unavailable, or age was b7 years at baseline.
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each relevant intelligence andMDvariable. Of particular interestweredif-
ferences between responders and non-responders. t-tests were also used
to explore differences in Phe indices between responders and non-
responders.
To avoid masking novel results that may drive future research, we
did not control for multiple comparisons and set our alpha level at
0.10.However, tomaintain statistical rigor,we considered results signif-
icant only when p-values less than our alpha threshold were associated
withmedium or large effect sizes. To adjust for bias due to small sample
size, Hedge's g and omega-squared (ω2)were used asmeasures of effect
size for t-test and ANOVA comparisons, respectively. Consistent with
conventions, g = 0.5 and ω2 = 0.06 designated medium effect sizes,
and g=0.8 andω2= 0.14 designated large effect sizes [13,27]. A grow-
ing body of research supports our statistical approach, emphasizing the
pitfalls of null hypothesis signiﬁcant testing [14,16,17,28] and the im-
portance of effect sizes and conﬁdence intervals [4,15,37].
3. Results
3.1. Omnibus results
As shown in Table 1, omnibus ANOVA results revealed signiﬁcant ef-
fects of group on IQ and Matrix Reasoning. With respect to MD, there
were signiﬁcant effects of group in 9 of 10whitematter ROIs: the hippo-
campus, putamen, prefrontal cortex, optic radiation, posterior parietal-
occipital, centrum semiovale, and genu, body, and splenium of the cor-
pus callosum. The effect of group on Vocabulary was not signiﬁcant, nor
was the effect of group on MD in the thalamus; as such, these variables
were excluded from further analyses.
3.2. Control group comparisons
Although not the central focus of our study, to provide a normative
context, we evaluated differences in intelligence and MD between
controls and each of our PKU groups (see Table 2). Regarding intelli-
gence, IQ was signiﬁcantly poorer for non-responders than controls. In
addition, Matrix Reasoning performance was signiﬁcantly poorer for
both responders and non-responders than controls. In terms of white
matter integrity results, MDwas signiﬁcantly lower for both responders
and non-responders than controls in the putamen, prefrontal cortex,
optic radiation, posterior parietal-occipital, centrum semiovale,
and genu of the corpus callosum. MD was also signiﬁcantly lower for
non-responders than controls in the hippocampus and body and
splenium of the corpus callosum. Thus, there were signiﬁcant ﬁndings
Table 1
Omnibus results comparing intelligence andMD among responders, non-responders, and
controls.
Statistical ﬁndings
F p ω2
Intelligence
IQ 4.69 0.02 0.15*
Vocabulary 0.91 0.41 b0.01
Matrix reasoning 7.11 b0.01 0.23*
ROI
Hippocampus 5.82 b0.01 0.20*
Putamen 5.63 b0.01 0.19*
Prefrontal 8.50 b0.01 0.28*
Optic radiation 12.43 b0.01 0.37*
Parietal-occipital 18.16 b0.01 0.47*
Centrum semiovale 10.73 b0.01 0.33*
Thalamus 1.19 0.32 b0.01
Genu of CC 15.81 b0.01 0.43*
Body of CC 9.01 b0.01 0.29*
Splenium of the CC 3.37 b0.05 0.11*
Note: asterisks denote statistically signiﬁcant results; F = variance between groups/vari-
ance within groups; ω2 = omega-squared; degrees of freedom= (2, 38) for intelligence
variables and (2, 36) for ROIs.
Table 3
Mean (SD) and statistical ﬁndings comparing indices of Phe control in responders and
non-responders.
Statistical ﬁndings
Phe (μmol/L) Responders Non-responders t p Hedge's g 95% CI
Baseline
Mean (SD) 588.3 (391.0) 746.2 (353.4) 1.13 0.14 0.41 −81.2
Range 135.5–1598.3 179.8–1271.3
Screening
Mean (SD) 254.4 (181.9) 789.6 (415.4) 4.64 b0.01 1.56* 336.7
Range 69.5–741.6 184.5–1541.8
% Reduction
Mean (SD) 53.0 (16.1) −6.7 (27.0) 7.38 b0.01 2.55* 45.9
Range 32.2–87.4 −71.6–16.6
Lifetime Mean
Mean (SD) 506.8 (262.9) 566.3 (243.2) 0.63 0.27 0.23 −102.7
Range 250.3–1033.7 179.8–1093.2
Lifetime SD
Mean (SD) 213.1 (92.7) 285.2 (145.4) 1.62 0.06 0.56* −3.85
Range 52.8–343.3 91.3–700.4
IDC
Mean (SD) 506.2 (240.8) 634.0 (316.9) 1.23 0.11 0.46 −48.7
Range 236.6–1000.2 205.4–1435.8
Notes: asterisks indicate statistically signiﬁcant between-group difference; upper bound
of all one-tailed conﬁdence intervals is inﬁnity.
Table 2
Mean (SD) and statistical ﬁndings comparing controls vs. responders and controls vs. non-responders.
Statistical ﬁndings
Control vs. Responders Control vs. Non-responders
Control Responders Non-responders t p Hedge's g 95% CI t p Hedge's g 95% CI
Intelligence
IQ 108.5 (10.6) 104.2 (10.9) 95.6 (12.5) 1.01 0.16 0.39 −3.02 2.96 b0.01 1.07* 5.48
Matrix reasoning 113.4 (9.9) 104.4 (11.4) 97.6 (11.4) 2.12 0.02 0.81* 1.12 3.92 b0.01 1.42* 5.95
ROI
Hippocampus 0.84 (0.02) 0.87 (0.08) 0.79 (0.06) 1.24 0.88 0.48 −0.07 2.91 b0.01 1.05* 0.02
Putamen 0.71 (0.03) 0.69 (0.04) 0.66 (0.05) 1.90 0.04 0.74* 0.00 3.47 b0.01 1.26* 0.03
Prefrontal 0.74 (0.05) 0.72 (0.03) 0.67 (0.05) 1.38 0.09 0.53* N−0.01 3.64 b0.01 1.38* 0.04
Optic radiation 0.84 (0.04) 0.79 (0.08) 0.70 (0.08) 1.72 0.05 0.67* N−0.01 5.59 b0.01 2.01* 0.09
Parietal-occipital 0.84 (0.05) 0.75 (0.08) 0.65 (.09) 3.45 b0.01 1.34* 0.04 6.18 b0.01 2.26* 0.13
Centrum Semiovale 0.73 (0.03) 0.68 (0.07) 0.61 (0.08) 2.31 0.02 0.90* 0.01 5.3 b0.01 1.89* 0.08
Genu of CC 0.83 (0.09) 0.71 (0.08) 0.64 (0.09) 3.59 b0.01 1.39* 0.07 5.23 b0.01 2.02* 0.13
Body of CC 0.85 (0.06) 0.82 (0.09) 0.73 (0.06) 0.99 0.17 0.38 −0.02 4.75 b0.01 1.80* 0.07
Splenium of CC 0.69 (0.05) 0.71 (0.08) 0.64 (0.07) 0.85 0.80 0.33 −0.07 1.95 0.03 0.72* 0.01
Notes: asterisks indicate statistically signiﬁcant between-group difference; upper bound of all one-tailed conﬁdence intervals is inﬁnity.
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in 6 of 9 ROIs for responders and all 9 ROIs for non-responders,
replicating ﬁndings from prior studies demonstrating poorer cognition
and white matter integrity in individuals with PKU relative to controls
(e.g., [3,44]).
3.3. Responder and non-responder comparisons
3.3.1. Phenylalanine
Group differences in baseline Phe, screening Phe, percent reduction
in Phe, lifetime mean Phe, lifetime SD Phe, and IDC were evaluated be-
tween responders and non-responders (see Table 3). Baseline Phe was
not signiﬁcantly different between responders and non-responders, al-
though in absolute terms baseline Phe was higher for non-responders.
As expected given their central roles in determining groupmembership,
signiﬁcant differences in screening Phe and percent reduction in Phe in-
dicated that blood Phe levels were reduced to a greater extent for re-
sponders than non-responders following implementation of treatment
with BH4. A signiﬁcant difference in SD Phe also emerged, indicating
that variability in Phe over the lifetime was greater for non-responders
than responders. In contrast, there were no signiﬁcant differences in ei-
ther mean Phe over the lifetime or IDC.
3.3.2. Intelligence
Given signiﬁcant ANOVA results, possible between-group differ-
ences in IQ and Matrix Reasoning were assessed in responders and
non-responders (see Table 4). In both comparisons, non-responders
scored signiﬁcantly poorer than responders. To situate these results
within the context of the single identiﬁed group difference in Phe
control, we examined correlations between intelligence and SD Phe in
responder and non-responder groups; no results were signiﬁcant.2
3.3.3. White matter integrity
Group differences in MD between responders and non-responders
were similarly evaluated in ROIs for which omnibus results were
signiﬁcant (see Table 4). Signiﬁcant results emerged in all 9 ROIs (hip-
pocampus, putamen, prefrontal cortex, optic radiation, posterior parie-
tal-occipital, centrum semiovale, and genu, body and splenium of the
corpus callosum), with lower MD for non-responders than responders.
Irrespective of statistical signiﬁcance, the chance odds that MD emerges
numerically lower (and therefore farther from the value of controls) for
non-responders than responders across all 9 ROIs is 0.0020.
Consistentwith our ROIﬁndings, TBSS analyses revealedwidespread
differences inMD (see Fig. 1A), with lowerMD for non-responders than
responders. We also examined white matter integrity in relation to SD
Phe over the lifetime and found that higher SD Phe was associated
with lower MD for non-responders (see Fig. 1B) but not responders.
4. Discussion
Previous studies have identiﬁed biochemical and genotypic differ-
ences between BH4 responders and non-responders with PKU [22,25,
26,34]. However, very little research has sought to identify cognitive
2 Baseline Phe, mean Phe, and IDC were not included in correlational analyses because
they did not differ signiﬁcantly between responders and non-responders; screening Phe
and percent reduction in Phe were not included because they determined group
membership.
Fig. 1. TBSS ﬁndings indicating (A) signiﬁcantly lowerMD in non-responders than responders and (B) a signiﬁcant inverse correlation betweenMD and SD Phe in non-responders. Notes:
green=TBSS skeleton; red= p b 0.05, orange= p b 0.03, and yellow= p b 0.01. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to theweb version
of this article.)
Table 4
Mean (SD) and statistical ﬁndings comparing intelligence and MD in responders and non-responders.
Statistical ﬁndings
Responders Non-responders t p Hedge's g 95% CI
Intelligence
IQ 104.2 (10.9) 95.6 (12.5) 1.98 0.03 0.71* 1.2
Matrix reasoning 104.4 (11.4) 97.6 (11.4) 1.60 0.06 0.58* −0.4
ROI
Hippocampus 0.87 (0.08) 0.79 (0.06) 2.83 b0.01 1.07* 0.03
Putamen 0.69 (0.04) 0.66 (0.05) 1.63 0.06 0.60* N−0.01
Prefrontal 0.72 (0.03) 0.67 (0.05) 2.89 b0.01 1.06* 0.02
Optic radiation 0.79 (0.08) 0.70 (0.08) 2.92 b0.01 1.09* 0.04
Parietal-occipital 0.75 (0.08) 0.65 (.09) 2.87 b0.01 1.06* 0.04
Centrum semiovale 0.68 (0.07) 0.61 (0.08) 2.30 0.02 0.86* 0.02
Genu of CC 0.71 (0.08) 0.64 (0.09) 2.11 0.02 0.78* 0.01
Body of CC 0.82 (0.09) 0.73 (0.06) 2.83 b0.01 1.07* 0.03
Splenium of CC 0.71 (0.08) 0.64 (0.07) 2.29 0.02 0.86* 0.02
Notes: asterisks indicate statistically signiﬁcant between-group difference; upper bound of all one-tailed conﬁdence intervals is inﬁnity.
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and neural differences between responders and non-responders. The
present study aimed to address this gap in the literature by investigating
baseline (i.e., prior to treatment with BH4) differences in indices of Phe
control, intelligence, and white matter integrity between individuals
with PKU who were subsequently identiﬁed as BH4 responders and
non-responders.
To situate our results within the context of previous research, a ma-
jority of which investigated cognitive performance andwhitematter in-
tegrity in individuals with PKU relative to controls [3,5,12], analyses
were conducted separately comparing intelligence and MD in re-
sponders and non-responders relative to controls. Consistent with
prior research [2,3,33,35], results indicated that individuals with PKU,
regardless of response to BH4, exhibited poorer intelligence and white
matter integrity than controls.
Turning to our central focus, we evaluated group differences be-
tween responders and non-responders. With respect to Phe, screening
Phe and lifetime SD Phe were signiﬁcantly higher for non-responders
than responders, whereas percent reduction in Phe was signiﬁcantly
lower; there were no signiﬁcant differences in baseline Phe, lifetime
mean Phe, or IDC prior to treatment. Because screening Phe and percent
reduction in Phe determined group status, differences between re-
sponders and non-responders were expected. The remaining indices
of Phe control can be classiﬁed as quantiﬁers of variability in Phe (SD
Phe) or Phe concentration (baseline Phe, mean Phe, IDC). As such, Phe
variability but not concentration distinguished responders fromnon-re-
sponders, positioning SD Phe as a potential predictor of response to BH4.
With respect to intelligence, signiﬁcant differences in IQ and Matrix
Reasoning standard scores were observed, with poorer scores for non-
responders than responders. A similar pattern emergedwhen neuroim-
aging data were examined, reﬂecting poorer white matter integrity for
non-responders than responders prior to treatment with BH4. Speciﬁ-
cally, MD was numerically lower for non-responders than responders
in all 9 ROIs submitted to post-hoc analyses (the hippocampus, puta-
men, prefrontal cortex, optic radiation, posterior parietal-occipital, cen-
trum semiovale, and genu, body, and splenium of the corpus callosum).
Corroborating ROI ﬁndings, TBSS analyses revealed that signiﬁcantly
poorer white matter integrity for non-responders than responders was
widespread. Additionally, TBSS analyses revealed signiﬁcant inverse
correlations between MD and SD Phe in non-responders but not re-
sponders, again pointing to the possible predictive utility of SD Phe.
Collectively, results from our study indicate that BH4 non-re-
sponders differ from responders on the basis of variability in Phe over
the lifetime and a number of variables reﬂecting intelligence and
white matter integrity. It is possible that more ﬁne-grained estimates
of effect size and/or additional signiﬁcant differences in Phe, intelli-
gence, and white matter integrity might have been identiﬁed in a larger
sample. Because PKU is a rare disorder affecting b0.01% of the United
States population [7], recruitment of large samples is inherently difﬁ-
cult, but through collaborative efforts future studies might address our
sample size limitation. In turn, in conjunction with genotypic data,
Phe, intelligence, and white matter integrity data might be used to de-
velop a powerful predictive model of response to BH4 in a larger sample
of individuals with PKU.
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